ClinicalTrials.gg
RecruitingNCT03512132DID&NEPHROUpdated Oct 30, 2026

Study of High Density Lipoprotein Function in Type 1 Diabetic Patients With Nephropathy

An observational study in Type 1 Diabetes, sponsored by Centre Hospitalier Universitaire Dijon. Recruiting at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Centre Hospitalier Universitaire Dijon · Observational

How we know

From the registry’s dates

  • Started Apr 2018; still recruiting 8 years 6 months later.
Updated Oct 30, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 271 studies in Diabetes Mellitus, Type 1 with a site in France — 39 open to participants now, 45 under way, 8 of them phase 3. Diabetes Mellitus, Type 1 · France.

Planned enrollment
32nd of 78
200 · median 153
Started
2018
with 8 others
Observational
78 of 271
22 open now
Primary completion
2027-10
later than 24 of 44 live
Registered
150th of 271
by date

Among the 271 studies in Diabetes Mellitus, Type 1 with a site in France, this one is the 32nd largest by planned enrollment of the 78 observational ones that give a count, is one of 9 that started in 2018, is one of 78 observational ones, reaches primary completion later than 24 of the 44 other live ones, and was the 150th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

39 of the 271 studies in Diabetes Mellitus, Type 1 with a site in France are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 271 studies in Diabetes Mellitus, Type 1 with a site in France, or all of them as a file.
02

Study summary

A number of arguments suggest that the deterioration in high density lipoproteins (HDL) functioning may worsen with the development of nephropathy during type 1 diabetes (T1D).

The objective of this study will be to investigate to what extent nephropathy in T1D patients in the microalbuminuria and macroalbuminuria stages, compared to T1D patients without nephropathy, is associated with an alteration in HDL functionality and changes in HDL size and composition (lipids with detailed study of phosphates and sphingolipids, main lipoproteins, inflammatory markers).

03

Conditions studied

  • Type 1 Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

patients treated in the Endocrinology, Diabetology or Nephrology departments of the CHU Dijon Bourgogne or in local nephrology or diabetology practices

Eligibility criteria

Inclusion Criteria:

INCLUSION CRITERIA GROUP C (CONTROLS) :

  • age > 18 years
  • a person who has given oral consent
  • Non-diabetics
  • Fasting plasma glucose \< 6.10 mmol/L (1.1 g/L)
  • Triglyceridemia \< 1.7 mmol/L (1.5 g/l)
  • HDL-C concentration > 1.30 mmol/L (for women and 1.03 mmol/L for men)
  • Glomerular filtration flow rate > 90 mL/min/1.73m2 (These thresholds correspond to the standard thresholds for these parameters)

INCLUSION CRITERIA GROUP T1D-N (WITH NORMAL ALBUMINURIA) :

  • age > 18 years
  • a person who has given oral consent
  • Diabetic type 1 (based on the patient's clinical history and/or the presence of anti-glutamate decarboxylase autoantibodies and/or plasma C-peptide less than 0.5 ng/l)
  • between 6 and 9%.
  • normal albuminuria (albumin/creatinine ratio \< 2.5 mg/mmol in men and \< 3.5 in women)
  • > 90 mL/min/1.73m2

INCLUSION CRITERIA GROUP T1D-MICRO (WITH MICROALBUMINURIA)

  • age > 18 years
  • a person who has given oral consent
  • Diabetic type 1 (based on the patient's clinical history and/or the presence of anti-glutamate decarboxylase autoantibodies and/or plasma C-peptide less than 0.5 ng/l)
  • HbA1c between 6 and 9%.
  • Microalbuminuria (albumin/creatinine ratio > 2.5 mg/mmol in men and > 3.5 in women, and \< 30 mg/mmol)
  • glomerular filtration rate > 90 mL/min/1.73m2

INCLUSION CRITERIA GROUP T1D-MACRO (WITH MACROALBUMINURIA)

  • age > 18 years
  • a person who has given oral consent
  • Diabetic type 1 (based on the patient's clinical history and/or the presence of anti-glutamate decarboxylase autoantibodies and/or plasma C-peptide less than 0.5 ng/l)
  • HbA1c between 6 and 9%.
  • Macroalbuminuria (albumin/creatinine ratio > 30 mg/mmol)
  • glomerular filtration rate > 45 mL/min/1.73m2

Exclusion Criteria:

  • Protected adult
  • Patient not affiliated to a social security scheme
  • Pregnant or breastfeeding woman
  • Drugs interfering with lipid metabolism outside insulin for DT1 : hypolipidemic (only for patients included in the DT1-micro group), , estroprogestogens, retinoic acid, antiproteases.
  • > 30 kg/m2
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • control

    Biological: Blood samples · Biological: Urine sample

  • T1D with normal albumin levels

    Biological: Blood samples · Biological: Urine sample

  • T1D with macroalbuminuria

    Biological: Blood samples · Biological: Urine sample

  • T1D with microalbuminuria

    Biological: Blood samples · Biological: Urine sample

  • T1D with microalbuminuria and statins

    Biological: Blood samples · Biological: Urine sample

Interventions

  • BiologicalBlood samples

    5 EDTA tubes of 7ml and 1 dry tube of 7 ml taken on an empty stomach

  • BiologicalUrine sample

    Urine sample on an empty stomach

06

What researchers measure

Primary outcomes

  1. Ability to induce cholesterol efflux

    amount of cholesterol captured from cells expressed as %.

    Time frame: inclusion

  2. Nitric oxide synthesis

    variation in the presence of HDL compared to the basal state, i.e. in the absence of HDL

    Time frame: inclusion

  3. Anti-inflammatory effect

    variation in the expression of adhesion molecules (VCAM-1 \[vascular cell adhesion molecule 1\], ICAM-1 \[InterCellular Adhesion Molecule 1\] and E selectin) under the influence of TNF-alpha \[Tumor Necrosis Factor alpha\] in the presence of HDL compared to the absence of HDL.

    Time frame: inclusion

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2018 (actual). Primary completion is estimated for Oct 2027, 114 months after the start.

Of 248 non-industry observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 78. This study's planned 114 months is above that.

Counting every sponsor, half of 298 studies reached it within 28 months; a quarter within 12 and three quarters within 69.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Apr 2026 → Oct 2027 and completion Apr 2026 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2018
First posted
Apr 30, 2018
StartActual
Apr 24, 2018
Primary completionEst.
Oct 2027was Apr 2026
CompletionEst.
Oct 2027was Apr 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Apr 2026→Oct 2027
Oct 30, 2026
Study completion
Apr 2026→Oct 2027
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Primary completion Apr 2026→Oct 2027
    Study completion Apr 2026→Oct 2027
    + 3 other changes: index terms, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT03512132
Responsible party
Sponsor
First posted
Apr 30, 2018
Start date
Apr 24, 2018
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Oct 30, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion